[HTML][HTML] mTOR function and therapeutic targeting in breast cancer

SH Hare, AJ Harvey - American journal of cancer research, 2017 - ncbi.nlm.nih.gov
The mTOR pathway was discovered in the late 1970s after the compound and natural
inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces hygroscopicus …

mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential

G Lei, L Zhuang, B Gan - Bioessays, 2021 - Wiley Online Library
Ferroptosis, a form of regulated cell death triggered by lipid hydroperoxide accumulation,
has an important role in a variety of diseases and pathological conditions, such as cancer …

The therapeutic potential of mTOR inhibitors in breast cancer

LS Steelman, AM Martelli, L Cocco… - British journal of …, 2016 - Wiley Online Library
Rapamycin and modified rapamycins (rapalogs) have been used to prevent allograft
rejection after organ transplant for over 15 years. The mechanistic target of rapamycin …

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

SY Sun - Frontiers of Medicine, 2021 - Springer
The mammalian target of rapamycin (mTOR) critically regulates several essential biological
functions, such as cell growth, metabolism, survival, and immune response by forming two …

[HTML][HTML] miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET

Q Chen, D Jiao, J Wang, H Hu, X Tang, J Chen… - Oncotarget, 2016 - ncbi.nlm.nih.gov
MicroRNAs (miRNAs) play a critical role in drug resistance and epithelial-mesenchymal
transition (EMT). The aims of this study were to explore the potential role of miR-206 in …

Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway

Q Chen, D Yang, H Zong, L Zhu, L Wang, X Wang… - Oncogenesis, 2017 - nature.com
Stromal cell populations in the tumor microenvironment (TME) play a critical role in the
oncogenesis and metastasis of renal cell carcinoma. In this study, we found that there are α …

CTCF expression and dynamic motif accessibility modulates epithelial–mesenchymal gene expression

KS Johnson, S Hussein, P Chakraborty… - Cancers, 2022 - mdpi.com
Simple Summary Epithelial–mesenchymal transition (EMT) facilitates cell migration,
invasion, and, consequently, metastasis, which ultimately contributes to breast-cancer …

A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors

KW Evans, E Yuca, A Akcakanat, SM Scott… - Clinical Cancer …, 2017 - AACR
Background: Breast cancer patients who do not respond to neoadjuvant therapy have a poor
prognosis. There is a pressing need for novel targets and models for preclinical testing. Here …

Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities

A Brodziak, P Sobczuk, E Bartnik… - Nature Reviews …, 2019 - nature.com
Papillary renal cell carcinoma (pRCC) is the second most common renal cell carcinoma
(RCC) subtype and accounts for 10–15% of all RCCs. Despite clinical need, few …

Simultaneous targeting of bladder tumor growth, survival, and epithelial-to-mesenchymal transition with a novel therapeutic combination of acetazolamide (AZ) and …

SS Islam, RB Mokhtari, P Akbari, J Hatina, H Yeger… - Targeted …, 2016 - Springer
Background Current chemotherapies for advanced stage metastatic bladder cancer often
result in severe side effects, and most patients become drug resistant over time. Thus, there …